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Oral anticoagulation (OAC) therapy has long 
been proven to be an effective treatment in atrial 
fibrillation (AF) to prevent ischemic stroke and 
systemic thromboembolism. The clinical effec-
tiveness of OAC (such as vitamin K antagonist 
[VKA]) far exceeds that of the antiplatelet agents, 
and with the advent of non-vitamin K oral antico-
agulants (NOACs), the propensity to cause harm 
by treatment-related hemorrhage is reduced. 
Nevertheless, as a third of AF patients may also 
suffer from significant coronary artery disease 
[1], the use of aspirin and ADP-receptor (P2Y12) 
antagonists in combination with OAC is indicated 
after acute coronary syndrome (ACS) or revascu-
larization treatment with coronary angioplasty and 
stent implantation.
This creates a therapeutic dilemma amongst 
clinicians as extended period of combination treat-
ment of any OAC plus antiplatelets in AF patient 
post-acute coronary events or coronary stent im-
plantation would expose the patients to increased 
bleeding risk and even fatal bleeds [2–5]. Indeed, 
we are trying to juggle four balls in the air in this 
situation: preventing stroke related to AF, minimize 
recurrent cardiac ischemia, avoid stent thrombosis 
and the risk of serious bleeding.
Several international consensuses and recom-
mendations have provided guidance regarding the 
duration and intensity of antiplatelet and anticoagu-
lation treatment [1, 6, 7]. Decision making largely 
depends on patient’s individual hemorrhagic risk, 
nature and type of stent implanted. With better stent 
technology, there is even a move towards shorter 
periods requiring post-stent implantation of dual 
antiplatelet drugs. However, there is little informa-
tion regarding adherence to guidelines and resultant 
clinical outcomes in AF patients. Furthermore, there 
is even less research upon prediction of “new-AF” 
occurrence in patients who are post ACS.
In the current issue of “Cardiology Journal”, 
two articles are of interest. First, Maier et al. [8] 
used the Berlin metropolitan registries to inve-
stigate the use of antiplatelet agents and OAC 
amongst AF patients who have experienced ACS. 
The second article by Lau et al. [9] utilized a Hong 
Kong registry to investigate the possibility of 
using CHADS2 and CHA2DS2-VASc score to predict 
new-onset AF among ST elevation myocardial 
infarction (STEMI) survivors.
In the first article, Meier et al. [8] utilized 
“real-world” data from the Berlin AFibACS Regi-
stry to identify over a 46-month period 1,295 AF 
patients who had suffered ACS, of which > 99% 
possessed significant stroke risk (CHA2DS2-VASc 
score > 1). Out of these, 888 (68.6%) AF-ACS pa-
tients had stent implantation, 7% only with balloon 
angioplasty, and the rest treated conservatively. 
Amongst the patients who had undergone stent 
implantation, almost 60% received bare metal stent 
(BMS) and the rest received drug-eluting stents 
(DES). Unsurprisingly, the initial inpatient results 
demonstrated no statistical difference in major or 
minor bleeding risk by GUSTO criteria when com-
paring patients receiving DES or BMS. Inpatient 
outcomes nonetheless reveal significantly higher 
mortality among patients treated conservatively 
and with plain-old balloon angioplasty only as com-
pared to those receiving coronary stents.
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A few points merit comment. When reviewing 
the discharge medications, it is apparent that de-
spite majority of AF-ACS patients receiving dual 
antiplatelet treatment, over 50% of patients who 
have received coronary stents were discharged wi-
thout effective anticoagulation treatment. Among 
those receiving triple therapy (dual antiplatelets 
and anticoagulation agents), only over half were 
receiving OAC, while the rest received sub-cuta-
neous heparin. There was a tiny number of patients 
(2%) receiving NOACs in the form of dabigatran. 
Logistic regression analysis did reveal that incre-
asing CHA2DS2-VASc score as an important factor 
for triple therapy, and gradual improvement of the 
prescription rate of triple therapy over time.
Despite various guidelines, the results from 
Meier et al. [8] highlight the lack of coherent 
management strategies among clinicians for AF 
patients who had received revascularization the-
rapy for ACS. This may indicate persistent gaps 
in awareness among clinicians concerning mana-
gement of ACS in AF patients, or the aversion of 
anticoagulation use due to perception of bleeding 
risk among this patient group who are usually older 
and generally frailer.
These data are in perspective to a recent re-
trospective analysis by Bernard et al. [10] which 
demonstrated that the lack of OAC at discharge (for 
patients undergoing coronary stent implantation) is 
independently associated with over 2-fold increase 
in risk of death, stroke and systemic thromboembo-
lism. Other large registry data, such as those from 
Lamberts et al. [11] clearly show that combination 
treatment of OAC and antiplatelet agent is needed 
to ensure better clinical outcomes. On the other 
hand, regarding the use of dual or triple therapy 
debate, some data suggest that dual therapy using 
OAC with clopidogrel may be just as efficacious as 
triple therapy, but results in lower bleeding risks 
[12]. The choice of using NOAC as an effective 
OAC remains contentious as there is no prospec-
tive trial evidence thus far to support its use in this 
particular patient group.
What about the development of new onset AF 
post-ACS? In the second article, Lau et al. [9] utilized 
a Hong Kong local cardiac registry to follow 607 conse-
cutive STEMI survivors, who had no known prior AF, 
for a period of 63 months, with the aim of identifying 
new-onset AF or stroke in this patient group. With 
this approach, 83 new-onset AF and 29 ischemic 
strokes were noted during the follow-up period.
Subsequent analysis of patient demographics 
comparing new-AF with those without showed 
that the AF-STEMI subgroup was generally more 
likely to be elderly, female and had worse cardiac 
function, with a lower ejection fraction, and higher 
prevalence of heart failure. Perhaps unsurprisingly, 
these findings have confirmed the association be-
tween age and AF, but also the pathophysiological 
relationship between AF and heart failure [13]. 
In this instance, the propensity of developing AF 
was amplified by the acute coronary event (i.e. 
STEMI). The latter may have resulted in neuro-
humoral activation, precipitating catecholamine 
release and tachycardia, interstitial fibrosis and/ 
/or dysregulation of intra-cellular calcium. Indeed, 
better prescription of beta-blockers (rate-limiting) 
and statins (fibrosis or inflammation reducing) 
could have a seemingly protective effect in the 
non-AF group.
More importantly, Lau et al. [9] demonstrated 
that those with new-onset AF are more likely to 
have higher pre-event CHADS2 and CHA2DS2-VASc 
scores. Both CHADS2 and CHA2DS2-VASc scores 
predicted a greater incidence of AF, with a c-stati-
stics of 0.632 and 0.676, respectively. However, the 
sensitivity and specificity of both scoring systems 
to detect AF are only modest at best. Those STEMI 
survivors who developed new ischemic stroke had 
higher CHADS2 and CHA2DS2-VASc scores.
The findings from Lau et al. [9] have highli-
ghted the increased prevalence of AF and ischemic 
stroke among post-STEMI survivors, and emp-
hasized the need for greater vigilance and better 
surveillance for new onset AF among this at-risk 
patient group. Nonetheless, once AF has been 
detected, the shift should be to identify those who 
will not benefit from OAC and after individualized 
stratification of bleeding risk, offer the most appro-
priate antithrombotic treatment to the rest [14].
In conclusion, we can appreciate that although 
the treatment of AF patients suffering from acute 
ACS is improving, the use of OAC remains subop-
timal. A greater emphasis on the use of appro-
priate OAC would help prevent death and reduce 
thromboembolic risk. This is further emphasized 
by the findings from Lau et al. [9], demonstrating 
the increased incidence of AF and stroke among 
STEMI survivors. The two articles in this journal 
also highlight the need for more trials related to the 
use of dual or triple therapy in the prevention of 
ischemic stroke in AF patients receiving coronary 
stents, as well as the intensity of surveillance in 
post ACS patients to detect new-onset AF.
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